Pages that link to "Q34539764"
Jump to navigation
Jump to search
The following pages link to Targeting mTOR for cancer treatment. (Q34539764):
Displaying 12 items.
- Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). (Q33836807) (← links)
- CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway (Q33909085) (← links)
- Exploiting novel molecular targets in gastrointestinal cancers. (Q34382777) (← links)
- CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms (Q35987292) (← links)
- mTOR signalling in human cancer (Q36919646) (← links)
- Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma (Q37111796) (← links)
- In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities (Q39906054) (← links)
- Physiologically based pharmacokinetic models for everolimus and sorafenib in mice (Q42575030) (← links)
- Renal dysplasia/hypoplasia, Williams Syndrome phenotype and non-Hodgkin lymphoma in the same patient: only a coincidence? (Q46208191) (← links)
- The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review (Q47155916) (← links)
- Ovarian cancer (Q82238526) (← links)
- A Study of Pipeline Drugs in Neuroendocrine Tumors (Q84070923) (← links)